Chronic hepatitis B in children carried out of the hemochromatosis gene HFE

Purpose: to establish the frequency and clinical significance of mutant variations of the HFE gene polymorphism in chronic hepatitis B (CHB) in children with iron overload syndrome (IOS).

Materials and methods: 60 children with chronic hepatitis B with iron overload syndrome (IOS) were examined. When distributing children into groups, we took into account the criteria we developed for assessing the degree of life expectancy in children with CHB: CST>0.5 – mild degree of life expectancy (43,3% of children), CST˃0.5 – mild degree of life expectancy (43,3% of children), CST˂0,5 – moderate severity of life expectancy (31,7% of children) and CST˂0,2 – severe degree of SPL (25,0%). Virological verification of HBV was performed by ELISA and PCR. Using PCR Real Time and molecular genetic analysis, HFE gene C282Y, H63D, S65C mutations were detected from amplified DNA using the PRONTO Hemochromatosis reagent kit (Israel). The transferrin saturation coefficient (CST) was calculated using the formula CST = sTfR / log10.Ft. Results:

Results: The study of the hemochromatosis gene HFE showed that the overwhelming majority (84,0%) of children with CHB with IOS were carriers of heterozygous, phenotypically different, mutant types. And only 16,0% of sick children were homozites of the wild (normal) HFE gene. Analysis of the phenotypic polymorphism of the hemochromatosis gene HFE revealed the presence of three point heterozygous mutations: H63D, S65C and combined variations in H63D / S65C, the latter of which is associated with severe forms of CHB and severe IOS.

Conclusion. Children with CHB with IOS are characterized by a high incidence of heterozygous mutations in the HFE gene, the phenotypic manifestations of which were S65C, H63D, H63D / S65C. The comparability of the heterozygous combined mutation H63D / S65C with severe forms of CHB and a severe degree of IOS gives grounds to consider this phenotype of the HFE gene as a factor in the progression of the disease.

1. Defresne F. Chronic hepatitis B in children: Therapeutic challenges and perspective / F. Defresne, E.Sokal // Gastroenterology and Hepatology. 2016; 32:368-371.

2. Lukina E.A Iron metabolism is normal and pathological. / Lukina E.A. [et al.] // Clinical Oncohematology. – 2015. – No. 4. – S. 355-361.

3. Bardou-Jacquet E. GNPAT variant associated with severe iron overload in HFE hemochromatosis. / E. Bardou-Jacquet [et al.] //Hepatology, 2015; 62 (6): 1917-1918.

4. Munoz M. Disorders of iron metabolism. Part 1: molecular basis of iron homeostasis. / M. Munoz [et al.] / J ClinPathol.- 2011; 64:281-286.

5. Tandara L. Iron metabolism: current facts and future directions. / Tandara L. [et al.] // BiochemiaMedica.- 2012.- 22(3).-Р.311-328.

6. Inoyatova F.I. Molecular mechanisms of disorders in the transport system of iron metabolism in refractory anemia in children with chronic viral liver disease. / F.I. Inoyatova [et al.] // Information letter. Tashkent – 2017.12 p.

7. Tarasova I.S. Development and scientific substantiation of screening for iron deficiency conditions in adolescents: author. diss. ... dr. honey. sciences. / I.S. Tarasova. – 2013.- 67s.

8. Warne C.D. HFE p.C282Y homozygosity predisposes to rapid serum ferritin rise after menopause: A genotype-stratified cohort study of hemochromatosis in Australian women. / C.D. Warne [et al.] // J Gastroenterol Hepatol. 2017; 32 (4): 797-802.

9. Powell L.W. Haemochromatosis. / L.W. Powell Lancet. [et al.] // 2016; 388(10045): 706-716.

10. Tarasova N.E. Ferrokinetics and mechanisms of its regulation in the human body. / N.E. Tarasova [et al.]. // Journal of fundamental medicine and biology.-2012. – No. 1. S.10-16.

11. Voloshina N.B. Hemochromatosis is the current state of the problem. / N.B. Voloshina [et al.] // Therapeutic Archive. – 2018; 03: S.107-112

12. Wood M.J. Serum ferritin concentration predicts hepatic fibrosis better than hepatic iron concentration in human HFEHaemochromatosis. / M.J. Wood [et al.] // Liver International. 2017; 37(9): 1382-1388.

13. Bacon В.R. Diagnosis and management of management of hemochromatosis: 2011 Practice Guideline by the American Association for the Study of Liver Diseases. / Bacon В.R. [et al.] // Hepatolog. 2011; 54: 328-343.

14. Paltsev I.V. Mutations of the HFE gene as a factor in the development of hemochromatosis in patients with chronic diffuse liver diseases. / I.V. Pal’tsev [et al.]. // Problems of health and ecology.-2010.-S.-56.

15. Powell L.W. Haemochromatosis. / L.W. Powell, R.C. Seckington, Y. Deugnier [et al.] // Lancet. 2016; 388(10045): 706-716.

16. Salama K. M. Liver Enzymes in Children with beta-Thalassemia Major: Correlation with Iron Overload and Viral Hepatitis. / K. M. Salama [et al.] // OA Maced J Med Sci. 2015 Jun 15; 3(2):287-292.

17. Brissot P. Non-transferrin bound iron: a key role in iron overload and iron toxicity. / P. Brissot [et al.] // Biochim. Biophys. Acta.-2012; 1820:401-408.

18. Moretti D. Relevance of dietary iron intake and bioavailability in the management of HFE hemochromatosis: a systematic review. / D. Moretti [et al.] // American Journal of Clinical Nutricion. 2013; 98 (2): 468-479.

19. Lokhmatova M.E. Genetically determined disorders of iron metabolism. / M.E. Lokhmatova [et al.] // Questions of hematology / oncology and immunology in pediatrics. – 2017; No. 3: P.83-91.

20. Delatycki M.B. Reduced mortality due to phlebotomy in moderately iron-loaded HFE haemochromatosis? The need for clinical trials. M.B. Delatycki [et al.] // Journal of Hepatology. 2015; 63 (1): 282-283.

21. Tuluzanovskaya I.G. Mutations in the HFE gene responsible for hereditary hemochromatosis in patients with WilsonKonovalov disease. / IG Tuluzanovskaya [et al.] // Experimental and clinical gastroenterology. – 2018. – No. 11. P.33-37.

22. A. Budnevsky. Erythroferrone as an erythroid regulator of iron metabolism. / A.V. Budnevsky [et al.] // Hematology and Transfusiology. – 2016 .-- 61 (3). S.161-163.

23. Brissot P. Genetic hemochromatosis. / P. Brissot, T. Cavey, M. Ropert, P. Guggenbuhl [et al.] // Pathophysiology, diagnostic and therapeutic management. Presse Med. – 2017. – V.46 (12) – P. 288–295.

24. Solovieva A.V. A clinical case of hereditary hemochromatosis. / A.V. Solovyova [et al.] // Clinical observations. – 2018. Volume 99. -№6. S. 998-1003.

25. Krivosheev A.B. Molecular genetic studies in chronic diffuse liver diseases. / A.B. Krivosheev [et al.] // Experimental and clinical gastroenterology. – 2020. – Issue 182. – No. 10. P.96-100.

26. Classification of chronic hepatitis: diagnosis, determination of the severity and stage of the course / Desmet V., Gerber M., Hootnagle I. et al. //R.Zh.G.G.K.-1995.-№2.-С.38-45

27. Inoyatova F.I. Molecular mechanisms of disorders of the transport system of iron metabolism in refractory anemia in children with chronic viral liver pathology. / F.I. Inoyatova [et al.] // Information letter. Tashkent – 2017.12 p.

28. Kondratova M.A. Mutations in the HFE gene in patients with non-alcoholic fatty liver disease, features of metabolic disorders. / M.A. Kondratova [et al.] // Experimental and clinical gastroenterology. – 2017; 145 (9): 18-24.